Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

itor use, concomitant use of methotrexate (MTX), and disease duration (<2 y vs greater than or equal to 2 y). Treatment effect differences between subgroups were assessed by interactions (treatment by covariate) at 10% significance level.

Active RA patients with inadequate response to greater than or equal to 1 DMARD were randomized 4:1 to CZP 400mg (n=851) at Weeks 0, 2 and 4 followed by 200mg every 2 weeks or placebo injection (control, n=212) every 2 weeks added to current therapy. PROs included fatigue (Fatigue Assessment Scale [FAS; 0–10 numeric rating scale]), pain (0–100mm visual analogue scale [VAS]), and patient's global assessment of disease activity (PtGA, 0–100mm VAS). The minimal clinically important difference (MCID) is a clinically relevant change in a patient's status. The percentage of patients reporting MCIDs was determined: greater than or equal to 1 for FAS, greater than or equal to 6 for MOS-SPI, and greater than or equal to 10mm for pain-VAS and PtGA. Correlations between PROs and DAS28 were also assessed (Pearson correlations [rho], CZP group only).

About CIMZIA®

Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderat
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014 /PRNewswire/ ... today announced that the U.S. Food and Drug ... patient enrollment and dosing of PEGPH20 in SWOG,s ... is designed to evaluate Halozyme,s investigational drug PEGPH20 ... FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic ...
(Date:9/18/2014)... -- Australian biomarker discovery company Minomic International Ltd will ... prostate cancer screening test, planning to achieve US Food ... Minomic,s proprietary MiStat™ technology is a screening assay ... known as the MIL-38 antigen. This biomarker is present ... Researchers at 11 leading urology centres in ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... , ALLEGAN, Mich. , Jan. 19 ... release financial results for its second quarter fiscal 2010 on Tuesday, ... Company will conduct a conference call at 10:00 a.m. (ET) ... Officer. , The conference call will be available live via webcast to ...
... LAKE CITY , Jan. 19 World Heart ... circulatory systems, announced today that the first U.S. implant of ... INTEGRIS Baptist Medical Center ("INTEGRIS") in Oklahoma City ... the first implant in the Levacor VAD bridge-to-transplant ("BTT") study, ...
Cached Medicine Technology:Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 3
(Date:9/18/2014)... York and London. (PRWEB) September 18, 2014 ... of Computer Aided Engineering software, today announced its new ... will be utilizing the CD-adapco simulation tool, STAR-CCM+® in ... team just announced its participation in the 35th America’s ... the 35th edition of the America’s Cup is sustainability, ...
(Date:9/18/2014)... parents eat more vegetables and drink less sugar, according ... Columbia. But it,s still not enough, the study goes ... when it comes to eating healthier at school , ... of socioeconomic status, may inform a child,s diet. , ... some post-secondary education were 85 per cent more likely ...
(Date:9/18/2014)... in German . ... have won the ,International Space Station Research Competition, with ... prize, the scientists will see the International Space Station ... involves crystallizing two proteins of the hepatitis C virus ... the International Space Station is scheduled to lift off ...
(Date:9/18/2014)... September 18, 2014 Relias Learning, the leader ... human services markets, today announced it has been named to ... private companies in America. , In the three-year period from ... up almost 2,000 spots on the Inc. 5000 list to ... , “The industries we serve continue to grow, and ...
(Date:9/18/2014)... According to a new market report published by ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - ... at USD 77607.7 million in 2013 and is expected to ... to reach an estimated value of USD 115474.9 million in ... growing at a rapid pace due to increasing prevalence of ...
Breaking Medicine News(10 mins):Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2Health News:Hepatitis C virus proteins in space 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4
... preventing medical support staff from completing orders for outpatient ... in a marked decrease in low-yield exams for patients, ... of Radiology . Many medical institutions request ... web-based radiology order entry systems. Some systems offer real-time ...
... and acceptance Three new reports describe biomarkers ... excellent and stable allograft function in the absence of ... transplants. Peter Heeger and Bernd Schrppel, at Mount Sinai ... commentary, the importance of these studies and how they ...
... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ...
... predisposition to delivering early, , MONDAY, May 24 (HealthDay News) ... to give birth to a baby who isn,t full-term, a ... who weren,t born early but had one or more siblings ... researchers. , "There was a suspicion that preterm birth might ...
... To prevent rejection of their new kidneys, kidney transplant recipients ... lives. A handful of people, out of the thousands who ... drugs without losing their kidneys. Researchers studying these rare ... their white blood cells, which may one day be used ...
... kids with blood sugar disease , MONDAY, May 24 (HealthDay ... enteroviruses -- which can cause viral meningitis -- and diagnoses ... how the two might be linked, but the findings suggest ... for diabetes in its early stages, lead researcher Antonio Toniolo, ...
Cached Medicine News:Health News:Simple change results in fewer unnecessary imaging exams for patients 2Health News:JCI table of contents: May 24, 2010 2Health News:JCI table of contents: May 24, 2010 3Health News:JCI table of contents: May 24, 2010 4Health News:JCI table of contents: May 24, 2010 5Health News:JCI table of contents: May 24, 2010 6Health News:JCI table of contents: May 24, 2010 7Health News:JCI table of contents: May 24, 2010 8Health News:JCI table of contents: May 24, 2010 9Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 2Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 3Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 4Health News:Women Born Early More Apt to Have Preterm Baby 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 3Health News:Viral Infection Could Be Marker for Type 1 Diabetes 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: